Navigation Links
Valeant Pharmaceuticals To Announce 2013 First Quarter Results On May 2, 2013
Date:4/16/2013

MONTREAL, April 16, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will host a conference call and a live Internet webcast along with a slide presentation on Thursday, May 2, 2013 at 7:30 a.m. ET (4:30 a.m. PT) to discuss results for the 2013 first quarter.

The dial-in number to participate on this call is (877) 876-8393, confirmation code 41820189.  International callers should dial (973) 200-3961, confirmation code 41820189. A replay will be available approximately two hours following the conclusion of the conference call to Thursday, May 9, 2013, and can be accessed by dialing (855) 859-2056 or (404) 537-3406, confirmation code 41820189.

The webcast and slide presentation will be hosted in the investor relations section of its corporate Web site at www.valeant.com. Participants should allow approximately five to 10 minutes prior to the call's start time to visit the site and to download any streaming media software needed to listen to the Internet webcast. An online archive of the webcast will be available following the end of the live call in the webcast archive portion of the investor relations section at www.valeant.com.

About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics.  More information about Valeant can be found at www.valeant.com.

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Provides Update to Recent Event
2. Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash
3. Valeant Pharmaceuticals Announces Private Exchange Offer
4. Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. for $19.75 Per Share in Cash
5. Valeant Pharmaceuticals Reports 2012 Fourth Quarter Financial Results
6. Valeant Completes Acquisition Of Natur Produkt In Russia
7. Valeant Pharmaceuticals To Announce 2012 Fourth Quarter Results On February 28, 2013
8. Valeant Completes Acquisition of Medicis and Announces Date of 2013 Financial Guidance Conference Call
9. Valeant Pharmaceuticals And Galderma Agree On Revised Agreement Terms
10. Valeant Pharmaceuticals Announces New Management Appointments
11. Valeant Pharmaceuticals Announces Publication of Efinaconazole Phase III Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... YORK , Feb. 17, 2017  BioDigital, ... today the partnership of their 3D body mapping ... healthcare IT.  The new integration will be used ... an interactive model of the human body. BioDigital ... saves clinicians time, while also increasing the precision ...
(Date:2/16/2017)... Quest Diagnostics (NYSE: DGX ), ... announced that it has been named one of the ... The annual survey designated Quest Diagnostics as ... Pharmacy and Other Services" industry to attain Most Admired ... attain the designation. This is the second consecutive year ...
(Date:2/16/2017)... 16, 2017  Newly published research from the CVS ... the role a private retailer can play in restricting ... published online today in the American Journal of ... remove tobacco from all CVS Pharmacy stores reduced the ... an even greater impact on those who bought cigarettes ...
Breaking Medicine Technology:
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... on foundational and sustainable systems change designed to further positively impact the health ... Board of Trustees has long considered it our duty to seriously consider releasing ...
(Date:2/17/2017)... VA (PRWEB) , ... February ... ... FDA Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. 22, 2017 ... What are the critical reimbursement questions manufacturers should be asking before selecting ...
(Date:2/17/2017)... ... February 17, 2017 , ... Qualis Health, one ... in the 8th Annual DecisionHealth Platinum Awards in recognition of its innovative healthcare ... is recognized across multiple award categories, highlighting four of the organization’s current programs:, ...
(Date:2/17/2017)... ... February 17, 2017 , ... MAP Revenue ... that Karen Pilley has been promoted to Chief Executive Officer. , The ... paradigm – a shift that demands the transition from pay-for-service to pay-for-performance models. ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... sponsor and exhibitor at Molecular Medicine Tri-Conference February 20 – 22 in San ... Inspirata will showcase its anatomic and molecular pathology workflow solution, as well as ...
Breaking Medicine News(10 mins):